timelines -bta798 & inavir, page-2

JA,

1. Q2 = June Qtr so I would hope April, being first month of June Qtr, is our V-day.

2. "Data will be collected on both the efficacy and safety of BTA798. The primary efficacy endpoint is an assessment of the severity and duration of cold symptoms and their impact on patient functioning. Secondary endpoints include incidence and severity
of asthma symptoms, changes in lung function, and duration and intensity of viral shedding from the upper respiratory tract."

3. BTA always speak generally.... 5 years to NDA... so 2016.